Cerus Corporation (NASDAQ: CERS) announced that the company has entered exclusive agreements with key distributors to supply the INTERCEPT Blood System for platelet and plasma in Chile, Indonesia and Poland. These new distributor relationships broaden the company’s access to markets for the INTERCEPT Blood System, which is already marketed in over 30 countries in Europe, Asia and the Middle East.
“These new distribution agreements highlight the growing market demand for the INTERCEPT Blood System to inactivate harmful pathogens that may be present in donated blood,” said Claes Glassell, president and CEO of Cerus Corporation. “I am pleased to have established business relationships in Chile, Indonesia and Poland in keeping with our global commercialization strategy. Together, these new regions represent an estimated $25 million of new market opportunity for the INTERCEPT platelet and plasma systems.”
In July 2007, Cerus announced that the company is collaborating with Grifols S.A. to supply the INTERCEPT Blood System for platelets and plasma in Spain and Portugal. Based on the early success of this relationship, Cerus and Grifols have mutually agreed to expand the INTERCEPT Blood System marketing effort into Chile. Grifols has had commercial operations in Chile since 1992, with local headquarters in Santiago.
Cerus granted PT Medquest Jaya Global distribution rights in Indonesia as a collaboration to improve blood safety in Indonesia. Medquest is a leader for innovative blood safety technology distribution in Indonesia and other countries in Asia. Medquest supports key customers, including the Indonesian Red Cross, Indonesian hospitals and U.S. Naval Medical Research. The Indonesian Red Cross oversees a blood banking system consisting of 189 blood centers.
In Poland, Hemosystems Sobczak & Co has agreed to distribute the INTERCEPT Blood System. Hemosystems is based in Warsaw and specializes in the distribution of devices and disposables to the blood transfusion market.
Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. Cerus currently markets the INTERCEPT Blood System for both platelets and plasma in Europe and the Middle East. The Company is also pursuing regulatory approvals in the United States and other countries. The INTERCEPT red blood cell system is currently in clinical development.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.
This press release contains forward-looking statements. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation, statements including references to the commercial acceptance of the INTERCEPT Blood System. Words such as "believe," "should," "expect" and similar words or expressions or the negative of these words or expressions are intended to identify forward-looking statements. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation, risks associated with the commercialization and market acceptance of the INTERCEPT Blood System, as well as other risks detailed in the company's filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2007, and Quarterly Report on Form 10-Q for the three months ended March 31, 2008. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise.
William J. Dawson, Vice President, Finance & CFO
Porter Novelli Life Sciences
Jason I. Spark